Epigenome engineering: new technologies for precision medicine

Agustin Sgro, Pilar Blancafort

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Chromatin adopts different configurations that are regulated by reversible covalent modifications, referred to as epigenetic marks. Epigenetic inhibitors have been approved for clinical use to restore epigenetic aberrations that result in silencing of tumor-suppressor genes, oncogene addictions, and enhancement of immune responses. However, these drugs suffer from major limitations, such as a lack of locus selectivity and potential toxicities. Technological advances have opened a new era of precision molecular medicine to reprogram cellular physiology. The locus-specificity of CRISPR/dCas9/12a to manipulate the epigenome is rapidly becoming a highly promising strategy for personalized medicine. This review focuses on new state-of-the-art epigenome editing approaches to modify the epigenome of neoplasms and other disease models towards a more 'normal-like state', having characteristics of normal tissue counterparts. We highlight biomolecular engineering methodologies to assemble, regulate, and deliver multiple epigenetic effectors that maximize the longevity of the therapeutic effect, and we discuss limitations of the platforms such as targeting efficiency and intracellular delivery for future clinical applications.

Original languageEnglish
Pages (from-to)12453-12482
Number of pages30
JournalNucleic Acids Research
Volume48
Issue number22
DOIs
Publication statusPublished - 16 Dec 2020

Fingerprint

Dive into the research topics of 'Epigenome engineering: new technologies for precision medicine'. Together they form a unique fingerprint.

Cite this